Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273733 | 1.00 | SLC34A2 (0.49) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL273735 | 0.94 | SLC34A2 (0.49) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL268995 | 0.94 | SLC34A2 (0.49) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL273730 | 0.94 | SLC34A2 (0.50) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL266272 | 0.94 | SLC34A2 (0.50) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL267715 | 0.93 | SLC34A2 (0.47) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL273736 | 0.93 | SLC34A2 (0.47) | SLC34A2CYP3A4MAPTCYP2C9ACKR3 | |
| SCHEMBL267306 | 0.91 | SLC34A2 (0.49) | SLC34A2CYP3A4ACKR3MEN1NPC1 | |
| SCHEMBL274311 | 0.91 | SLC34A2 (0.49) | SLC34A2CYP3A4ACKR3MEN1NPC1 | |
| SCHEMBL267682 | 0.90 | SLC34A2 (0.57) | SLC34A2ACKR3MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | SLC34A2 6/4885CYP3A4 1856/4885MAPT 4195/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | SLC34A2 2/4885CYP3A4 1849/4885MAPT 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.